Patent ID: 8613920
Filing Date: 2013-12-24
Classification: A61K,A61P,C07K

Abstract:
1. A method of therapeutically treating Alzheimer's disease, comprising administering by intravenous infusion to a human patient suffering from the disease a dosage of an antibody that specifically binds to an N-terminal fragment of beta-amyloid peptide (Aβ) with a binding affinity of at least 10 7 M −1 , and monitoring the patient for posterior reversible encephalopathy syndrome (PRES) or vascular edema, wherein the method comprises the steps of: (a) administering a first dosage to the patient; (b) monitoring the patient and detecting the presence of PRES or vascular edema at a first time point; (c) optionally administering a second dosage to the patient after the monitoring in step (b) detects presence of PRES or vascular edema; (d) monitoring the patient and detecting the absence of PRES or vascular edema at a second time point; and (e) administering another dosage to the patient after the monitoring in step (d) indicates absence of PRES or vascular edema, wherein the dosages in (a) and (e) are higher than the dosage in (c) if a dosage is administered in (c).